Oxford COVID-19 trial of HCQ to continue despite WHO's temporary suspension of the drug

Despite World Health Organization's (WHO) suspending use of hydroxychloroquine (H) drug, Oxford University's Coronavirus trial is still going as planned. According to reports, United Kingdom drug watchdogs have given a green light to scientists to continue prescribing HCQ tablets to National Health Service (NHS) patients. 

According to  UK's Medicines and Healthcare products Regulatory ncy (MHRA), y do t see any safety concerns. However, University has temporarily blocked recruitment for Principle trial-- research on HCQ's effect on elderly COVID-19 patients (50 years to 64 years). Along with it, university has also halted enrollment of patients for trial across globe. Meanwhile, over 10,500 COVID-19 patients have reportedly taken in  Randomised Evaluation of COV-id19 RapY (RECOVERY) trial. 

Re: Trump accuses Twitter of 'stifling free speech' after tweet is flagged for misinformation

Oxford anunces Phase II & III

Meanwhile, on May 23, Oxford University scientists who are working to develop a vaccine for COVID-19 h started recruiting candidates for Phases II and III of human clinical trials on May 22. For Phase II trials, university has been seeking 10,260 candidates including children and older ults in order to study  effects of formulated drug on ir immune system. While for Phase III, y are seeking children d 5 to 12. Along with it, ults d between 56 to 69 and over of 70 have been also zeroed for research.

According to professor Andrew Pollard, he of Oxford Vaccine Group, clinical studies are progressing very well and researchers are w initiating studies to evaluate how well potential vaccine induces immune responses in older ults and to test wher it can provide protection in wider population.

Re: WHO Executive Group pauses solitary trial on HCQ to review data as ICMR expands its us

WHO pauses HCQ trial 

In a major decision, World Health Organisation (WHO)'s Executive Group, on Monday, decided to temporarily pause Hydroxychlorine (HCQ) trial while data collected so far is reviewed, anunced WHO chief Dr. Tedros in a press briefing. He ded that Executive Group's solidarity trial comprising of 10 countries will equately evaluate potential benefits and harms from this drug. Clarifying that or arms of trial were continuing, he ded that drugs hydroxychloroquine and chloroquine were generally safe for treating patients of autoimmune diseases or malaria.

Re: Trump says US to take action against China over Hong Kong issue by end of this week

Re: US President Trump spends Memorial Day retweeting sexist personal attacks on women